The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.a

Pneumonitis (interstitial lung disease/ILD)

Incidence estimates 4,5% in Japan (PMID 22610257) as opposed to 0.4% in the West (PMID 18438878). Possible explanations for the discrepancy at PMID 27004571

Publications

Tungjitviboonkun S, Bumrungratanayos N, Jitwimungsanon J

Erlotinib-associated interstitial pneumonitis with successful readministration.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2023 Jul 19;;10781552231190319 — 2023 Jul 19 — 10781552231190319

Yoshioka H, Komuta K, Imamura F, Kudoh S, Seki A, Fukuoka M

Efficacy and safety of erlotinib in elderly patients in the phase IV POLARSTAR surveillance study of Japanese patients with non-small-cell lung cancer.

Lung cancer (Amsterdam, Netherlands) 2014 Nov;86;201-6 — 2014 Nov — 201-6

Kubota K, Nishiwaki Y, Tamura T, Nakagawa K, Matsui K, Watanabe K, Hida T, Kawahara M, Katakami N, Takeda K, Yokoyama A, Noda K, Fukuoka M, Saijo N

Efficacy and safety of erlotinib monotherapy for Japanese patients with advanced non-small cell lung cancer: a phase II study.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2008 Dec;3;1439-45 — 2008 Dec — 1439-45

Spigel DR, Lin M, O'Neill V, Hainsworth JD

Final survival and safety results from a multicenter, open-label, phase 3b trial of erlotinib in patients with advanced nonsmall cell lung cancer.

Cancer 2008 Jun 15;112;2749-55 — 2008 Jun 15 — 2749-55

Bach JP, Kiessling AM, Kleinhans A, Faoro C, Gorg C, Riera-Knorrenschild J, Schwella N, Wagner HJ, Neubauer A

Pulmonary fibrosis in a patient treated with erlotinib.

Onkologie 2006 Jul;29;342-3 — 2006 Jul — 342-3